ACIUAC Immune SA

Nasdaq acimmune.com


$ 3.17 $ -0.27 (-7.85 %)    

Monday, 13-May-2024 11:20:00 EDT
QQQ $ 442.98 $ -0.41 (-0.09 %)
DIA $ 395.68 $ -0.72 (-0.18 %)
SPY $ 521.25 $ -1.34 (-0.26 %)
TLT $ 90.36 $ 0.03 (0.03 %)
GLD $ 216.27 $ -0.84 (-0.39 %)
$ 2.31
$ 3.44
$ 3.17 x 100
$ 3.21 x 100
$ 2.91 - $ 3.53
$ 1.90 - $ 5.14
150,715
na
229.15M
$ 0.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Market-Moving News for May 13th
05/13/2024 12:42:15

GME: 46% | GameStop shares are trading higher amid possible retail investor interest following a social media post by Roaring K...

 hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

 ac-immune-received-decision-to-grant-european-patent-ep3735411-1345-tetrahydro-2h-pyrido43-bindole-derivatives-for-the-treatment-alleviation-or-prevention-of-disorders-associated-with-tau-aggregates-like-alzheimers-disease

https://register.epo.org/application?number=EP21153153

 ac-immune-raises-50m-its-alzheimers-targeting-immunotherapy-advances-into-phase-2b-trial

AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35...

 ac-immune-appointed-interim-cfo-christopher-roberts-as-permanent-finance-chief

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative dise...

 alzheimers-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-others

Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain...

 hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

 ac-immune-q3-eps-020-down-from-017-yoy

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.20) per share. This is a 20 percent decrease over losses of $(0.17) pe...

 hc-wainwright--co-reiterates-buy-on-ac-immune-maintains-16-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION